Evidence map›Paper›PMID 35272019›Full record

SynthesisTravel medicine and infectious disease

COVID 19 and febrile neutropenia: Case report and systematic review.

Taner Kaya, Ahmet Dilek, Resat Ozaras, Ozlem Sahin Balcik, Hakan Leblebicioglu

Open access · greenAbstract readCase ReportsSystematic Review
In one paragraph

Synthesis in Travel medicine and infectious disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Taner KayaDepartment of Internal Medicine, VM Medicalpark Samsun Hospital, Samsun, Turkey. Electronic address: taner.kaya@medicalpark.com.tr.
Ahmet DilekIntensive Care Unit, VM Medicalpark Samsun Hospital, Samsun, Turkey; Istinye University, Faculty of Medicine, Istanbul, Turkey. Electronic address: adilekdr@yahoo.com.
Resat OzarasDepartment of Infectious Diseases, Medilife Health Group, Istanbul, Turkey. Electronic address: rozaras@yahoo.com.
Ozlem Sahin BalcikDepartment of Hematology, VM Medicalpark Samsun Hospital, Samsun, Turkey. Electronic address: drozlemsahinbalcik@gmail.com.
Hakan LeblebiciogluDepartment of Infectious Diseases, VM Medicalpark Samsun Hospital, Samsun, Turkey. Electronic address: hakanomu@yahoo.com.
Samsun University · TRUniversity of Health Sciences Antigua · AG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesIn pandemic conditions, patients with febrile neutropenia are also at risk of COVID-19. Aim of this systematic review is to evaluate COVID-19 cases presented with febrile neutropenia and provide information regarding incidence, clinical course and prognosis.

methodsWe systematically searched on COVID-19 and febrile neutropenia cases in PubMed, SCOPUS and Web of Science.

resultsA total of 19 febrile neutropenic patients were analyzed. A male predominance was noted. Eleven cases had hematological malignancies. Fourteen of the cases were previously received chemotherapy. Five patients had severe neutropenia: 3 had hematologic cancer and none died. 17 (89.5%) cases have pulmonary involvement and seven of them had severe disease with acute respiratory distress syndrome (ARDS). Three cases with ARDS were died. 12 of them received G-CSF for treatment. Five cases were developed respiratory failure after G-CSF use. Overall mortality was 15.8%, while death was not observed in patients without malignancy and solid organ tumors, the mortality rate was 27% in cases with hematological malignancies.

conclusionIn ongoing pandemic, febrile neutropenic patients should be precisely evaluated for COVID-19 disease. It should be remembered that there may not be typical signs and symptoms and laboratory findings of COVID-19 disease because of the immunosuppression.

Indexed as

COVID-19Febrile NeutropeniaHematologic NeoplasmsNeoplasmsRespiratory Distress SyndromeFemaleFeverGranulocyte Colony-Stimulating FactorHumansMaleGranulocyte Colony-Stimulating Factor

Identifiers

PMID35272019
PMCPMC8901240
OpenAlexW4220743524

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.